Pseudomonic acid, a new antibiotic for topical therapy.
Pseudomonic acid, a new wide-spectrum antimicrobial agent, was evaluated as a 2% formulation in a cream. Animal studies showed that this formulation was just capable of penetrating the skin. When administered parenterally to animals, pseudomonic acid was converted to inactive metabolites that were quickly eliminated from the body. When pseudomonic acid was applied as a cream to human skin, no sensitization was observed. In an open clinical study, sixty-eight patients with skin infections (mostly superficial conditions such as impetigo, infected eczema, folliculitis, or balanitis) applied pseudomonic acid cream three times a day for 5 days. In fifty patients the infections completely cleared within 2 days of the end of therapy, and considerable clinical improvement was noted in sixteen more. One patient stopped the treatment prematurely due to local burning pain, and one patient could not be evaluated clinically.
D000287:Administration, Topical; D000293:Adolescent; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004285:Dogs; D004311:Double-Blind Method; D005227:Fatty Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016712:Mupirocin; D051381:Rats; D012869:Skin Absorption; D012874:Skin Diseases, Infectious / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D005227:Fatty Acids; D016712:Mupirocin